Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-Concept Trial of NS-8 in Multiple Doses for Overactive Bladder
2005-001250-24Phase 2Completed
- Sponsor
- APOGEPHA
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of imidafenacin in overactive bladder (OAB) (4 arms), sponsored by APOGEPHA. Primary endpoints: Primary efficacy endpoint and Dose-response assessment. Started Jun 2005; status: completed.
02
Drugs
imidafenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2005-001250-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001250-24.